Our Generics Division
Our Watson Generics division develops, manufactures and markets products that are the therapeutic equivalent to their brand name counterparts. Our portfolio for this business includes products we have internally developed, products we have licensed, and products we distribute for third parties. We are the 3rd largest supplier of generic pharmaceutical products in the U.S., based on prescriptions dispensed1.
We offer one of the broadest generic product lines in the U.S., and with approximately 60 abbreviated new drug applications (ANDAs) pending with FDA, have one of the strongest pipelines in the industry.
Highlights
- Approximately 150 pharmaceutical product families in the portfolio
- 11 new products launched in 2008
- Filed 13 new ANDAs with FDA in 2008
- Generated approximately $1.5 billion in generic revenue during 2008
- Accounted for approximately 60% of total annual revenue at Watson
Therapeutic Areas
- Antibiotics
- Anti-inflammatories
- Depression
- Hypertension
- Oral contraceptives
- Pain management
- Smoking cessation
Competitive Advantages
- Portfolio of difficult-to-replicate products
- Excellent reputation of customer service
- Strong relationships with trade customers
1Source: IMS Health, December 2008
